The FDA’s AI Use Is Surging, and Its Internal Capacity Is Becoming a Policy Story
New data cited by Fierce Healthcare shows AI use jumping sharply across HHS, including a 148% increase at the FDA in 2025. The numbers suggest the government is becoming both a regulator of AI and an active user of it, which raises questions about capacity, consistency, and oversight.
The rapid rise in AI use across HHS is significant not only because of the scale, but because it changes the posture of the federal government. Agencies like the FDA are no longer just reacting to AI in the private sector; they are increasingly using the same kinds of tools internally to manage workloads, analyze information, and possibly accelerate review processes.
That creates both opportunity and tension. On one hand, AI could help agencies handle growing complexity with fewer resources. On the other hand, greater internal dependence on AI makes it more important that the government can explain its own use, document its limitations, and ensure consistency in decision-making.
The 148% jump at the FDA is particularly striking because the agency sits at the center of medical AI oversight. If its internal adoption is rising that quickly, it may shape how regulators think about acceptable risk, model governance, and the practical realities of oversight at scale.
The policy lesson is that capacity matters as much as rules. A regulator cannot credibly oversee a fast-moving technology if it lacks the tools and expertise to use it itself. That means the story is not just about adoption—it is about whether the government can build the operational competence needed to govern AI in healthcare.